Investigational Drug Information for Ganetespib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Ganetespib?
Ganetespib is an investigational drug.
There have been 32 clinical trials for Ganetespib.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., National Cancer Institute (NCI), and Emory University.
There are three hundred and thirty-three US patents protecting this investigational drug and three international patents.
Summary for Ganetespib
| US Patents | 333 |
| International Patents | 3,616 |
| US Patent Applications | 833 |
| WIPO Patent Applications | 592 |
| Japanese Patent Applications | 331 |
| Clinical Trial Progress | Phase 2 (2013-04-01) |
| Vendors | 67 |
Recent Clinical Trials for Ganetespib
| Title | Sponsor | Phase |
|---|---|---|
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | European Commission | Phase 2 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | Universitaire Ziekenhuizen Leuven | Phase 2 |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | University of Chicago | N/A |
Clinical Trial Summary for Ganetespib
Top disease conditions for Ganetespib
Top clinical trial sponsors for Ganetespib
US Patents for Ganetespib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ganetespib | See Plans and Pricing | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Ganetespib | See Plans and Pricing | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | See Plans and Pricing |
| Ganetespib | See Plans and Pricing | Bicyclic bromodomain inhibitors | Zenith Epigenetics Ltd. (Calgary, AB, CA) | See Plans and Pricing |
| Ganetespib | See Plans and Pricing | Glutaminase inhibitors and method of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Ganetespib | See Plans and Pricing | Constructs targeting AFP peptide/MHC complexes and uses thereof | EUREKA THERAPEUTICS, INC. (Emeryville, CA) | See Plans and Pricing |
| Ganetespib | See Plans and Pricing | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (Cambridge, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ganetespib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ganetespib | Australia | AU2015231053 | 2034-03-21 | See Plans and Pricing |
| Ganetespib | Brazil | BR112016021620 | 2034-03-21 | See Plans and Pricing |
| Ganetespib | Canada | CA2943339 | 2034-03-21 | See Plans and Pricing |
| Ganetespib | China | CN106231900 | 2034-03-21 | See Plans and Pricing |
| Ganetespib | Eurasian Patent Organization | EA201691896 | 2034-03-21 | See Plans and Pricing |
| Ganetespib | European Patent Office | EP3119199 | 2034-03-21 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
